

Additional file 1: Table S1. Statistically significant differences between unmatched patient groups (categorisation 1)

<b>Characteristics</b>		<b>Non-high blood eosinophil and low FeNO</b>	<b>Non-high blood eosinophil and medium FeNO</b>	<b>Non-high blood eosinophil and high FeNO</b>	<b>High blood eosinophil and low FeNO</b>	<b>High blood eosinophil and medium FeNO</b>	<b>High blood eosinophil and high FeNO</b>	<b>p-value</b>
<b>Categorised age group</b>	n (% non- missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	<0.0001
	Under 35	28 (9.5)	12 (16.7)	8 (30.8)	12 (9.8)	6 (9.0)	12 (44.4)	
	35–65	229 (77.4)	49 (68.1)	14 (53.8)	90 (73.8)	48 (71.6)	9 (33.3)	
	66–80	39 (13.2)	11 (15.3)	4 (15.4)	20 (16.4)	13 (19.4)	6 (22.2)	
<b>Sex</b>	n (% non- missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0028
	Male	93 (31.4)	25 (34.7)	14 (53.8)	52 (42.6)	37 (55.2)	10 (37.0)	
<b>Smoking status</b>	n (% non- missing)	245 (82.8)	62 (86.1)	22 (84.6)	101 (82.8)	60 (89.6)	22 (81.5)	0.0007

	Non-smoker	110 (44.9)	36 (58.1)	15 (68.2)	30 (29.7)	32 (53.3)	14 (63.6)	
	Ex-smoker	35 (14.3)	7 (11.3)	3 (13.6)	29 (28.7)	6 (10.0)	2 (9.1)	
	Current smoker	100 (40.8)	19 (30.6)	4 (18.2)	42 (41.6)	22 (36.7)	6 (27.3)	
<b>BMI</b>	n (% non-missing)	280 (94.6)	70 (97.2)	24 (92.3)	118 (96.7)	63 (94.0)	26 (96.3)	0.0022
	Mean (SD)	30.0 (6.7)	29.5 (6.1)	26.3 (5.3)	30.8 (7.6)	28.2 (7.1)	26.9 (6.4)	
<b>Eczema diagnosis</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0405
	Yes	78 (26.4)	23 (31.9)	5 (19.2)	49 (40.2)	17 (25.4)	11 (40.7)	
<b>Rhinitis diagnosis</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0270
	Yes	114 (38.5)	24 (33.3)	5 (19.2)	52 (42.6)	36 (53.7)	13 (48.1)	
<b>GERD active diagnosis</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0223
	Yes	50 (16.9)	5 (6.9)	1 (3.8)	13 (10.7)	10 (14.9)	0 (0.0)	

<b>Current peak flow</b>	n (% non-missing)	160 (54.1)	49 (68.1)	19 (73.1)	57 (46.7)	42 (62.7)	20 (74.1)	0.0285
	Mean (SD)	401.3 (102.9)	403.6 (112.7)	431.1 (123.3)	423.6 (132.1)	469.8 (111.2)	406.0 (142.4)	
<b>Predicted peak flow</b>	n (% non-missing)	158 (53.4)	49 (68.1)	19 (73.1)	57 (46.7)	42 (62.7)	20 (74.1)	0.0032
	Mean (SD)	495.7 (71.4)	503.2 (79.3)	542.6 (60.1)	526.8 (81.3)	534.8 (69.7)	505.8 (74.9)	
<b>FEV<sub>1</sub> % predicted groups</b>	n (% non-missing)	55 (18.6)	10 (13.9)	4 (15.4)	28 (23.0)	13 (19.4)	5 (18.5)	0.0456
	50% or less	12 (21.8)	1 (10.0)	1 (25.0)	10 (35.7)	9 (69.2)	1 (20.0)	
	>50% to <80%	13 (23.6)	4 (40.0)	1 (25.0)	8 (28.6)	0 (0.0)	1 (20.0)	
	80% to <100%	15 (27.3)	4 (40.0)	2 (50.0)	3 (10.7)	2 (15.4)	3 (60.0)	
	100%+	15 (27.3)	1 (10.0)	0 (0.0)	7 (25.0)	2 (15.4)	0 (0.0)	
<b>Asthma consultations</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0446

	Mean (SD)	1.8 (1.5)	2.3 (1.8)	2.5 (2.6)	1.7 (1.3)	1.9 (2.0)	2.3 (1.4)	
<b>Asthma related unplanned inpatient attendance</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0163
	Yes	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)	1 (3.7)	
<b>ICS/LABA prescriptions per patient</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0096
	Mean (SD)	4.2 (4.1)	3.2 (3.5)	2.5 (3.0)	4.9 (3.9)	4.2 (4.3)	3.2 (2.5)	
<b>ICS daily dose</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0454
	Mean (SD)	586.9 (503.5)	549.4 (477.0)	357.4 (349.2)	623.2 (497.7)	588.3 (523.4)	443.6 (342.1)	
<b>ICS inhalers</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0165
	Mean (SD)	7.0 (5.2)	5.9 (3.9)	4.3 (4.3)	6.9 (4.6)	6.9 (5.4)	5.1 (2.8)	
<b>ICS</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0043

<b>prescriptions</b>	missing)							
	Mean (SD)	5.6 (3.8)	4.5 (3.3)	3.3 (3.1)	5.5 (3.6)	5.1 (3.9)	4.4 (2.3)	
<b>Number of ICS containing inhalers</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0010
	1–3	90 (30.4)	24 (33.3)	17 (65.4)	36 (29.5)	23 (34.3)	7 (25.9)	
	4–6	76 (25.7)	25 (34.7)	4 (15.4)	27 (22.1)	16 (23.9)	14 (51.9)	
	≥7	130 (43.9)	23 (31.9)	5 (19.2)	59 (48.4)	28 (41.8)	6 (22.2)	
<b>Mean daily ICS dosage (µg)</b>	n (% non-missing)	296 (100.0)	72 (100.0)	26 (100.0)	122 (100.0)	67 (100.0)	27 (100.0)	0.0026
	<250	89 (30.1)	22 (30.6)	16 (61.5)	30 (24.6)	21 (31.3)	8 (29.6)	
	250 to <500	74 (25.0)	24 (33.3)	4 (15.4)	32 (26.2)	19 (28.4)	14 (51.9)	
	≥500	133 (44.9)	26 (36.1)	6 (23.1)	60 (49.2)	27 (40.3)	5 (18.5)	

All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥50 ppb; medium FeNO, 25 to <50 ppb; low FeNO <25 ppb; high blood eosinophil count defined as ≥0.300×10<sup>9</sup> cells/L; non-high blood eosinophil count <0.300×10<sup>9</sup> cells/L.

BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV, forced expiratory volume; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; LABA, long-acting β<sub>2</sub>-agonist; ppb, parts per billion; SABA, short-acting β<sub>2</sub>-agonist; SD, standard deviation

Additional file 1: Table S2. Statistically significant difference between unmatched patient groups (categorisation 2)

<b>Characteristics</b>		<b>Non-high eosinophil and non-high FeNO</b>	<b>Non-high eosinophil and high FeNO</b>	<b>High eosinophil and non-high FeNO</b>	<b>High eosinophil and high FeNO</b>	<b>p-value</b>
<b>Sex</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0177
	Male	113 (32.6)	19 (40.4)	74 (46.0)	25 (45.5)	
<b>Smoking status</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0115
	Non-smoker	138 (39.8)	23 (48.9)	45 (28.0)	31 (56.4)	
	Ex-smoker	40 (11.5)	5 (10.6)	32 (19.9)	5 (9.1)	
	Current smoker	111 (32.0)	12 (25.5)	58 (36.0)	12 (21.8)	
<b>BMI</b>	n (% non-missing)	331 (95.4)	43 (91.5)	155 (96.3)	51 (92.7)	0.0005

	Mean (SD)	29.9 (6.5)	27.8 (6.9)	30.4 (7.8)	26.7 (5.6)	
<b>BMI</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0411
	Underweight	1 (0.3)	0 (0.0)	2 (1.2)	1 (1.8)	
	Normal	81 (23.3)	19 (40.4)	36 (22.4)	20 (36.4)	
	Overweight	102 (29.4)	8 (17.0)	48 (29.8)	18 (32.7)	
	Obese	147 (42.4)	16 (34.0)	69 (42.9)	12 (21.8)	
<b>Mean daily ICS dosage (µg)</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0133
	<250	103 (29.7)	24 (51.1)	44 (27.3)	15 (27.3)	
	250 to <500	91 (26.2)	11 (23.4)	43 (26.7)	22 (40.0)	
	≥500	153 (44.1)	12 (25.5)	74 (46.0)	18 (32.7)	
<b>Asthma ATS exacerbations</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0403
	Mean (SD)	0.4 (0.7)	0.3 (0.5)	0.4 (0.8)	0.7 (0.9)	
<b>Medication</b>	n (% non-missing)	340 (98.0)	45 (95.7)	158 (98.1)	55 (100.0)	0.0062

<b>cost</b>	missing)					
	Mean (SD)	268.5 (228.1)	189.6 (222.1)	285.6 (238.2)	251.6 (231.6)	
<b>ICS daily dose</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0153
	Mean (SD)	587.2 (498.6)	399.9 (411.7)	601.5 (498.1)	555.9 (472.0)	
<b>ICS inhalers</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0219
	Mean (SD)	6.9 (5.1)	4.9 (4.0)	6.7 (4.5)	6.4 (5.3)	
<b>ICS prescriptions</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0100
	Mean (SD)	5.4 (3.7)	3.8 (3.3)	5.4 (3.6)	4.9 (3.6)	
<b>ICS/LABA prescriptions per patient</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0056
	Mean (SD)	4.1 (4.0)	2.6 (3.1)	4.7 (3.9)	3.9 (4.0)	
<b>Asthma related</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0177



<b>accident and emergency attendance</b>	Yes	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)	
<b>Asthma related unplanned inpatient attendance</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0002
	Yes	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.6)	
<b>FEV<sub>1</sub>/FVC ratio</b>	n (% non-missing)	45 (13.0)	8 (17.0)	21 (13.0)	10 (18.2)	0.0386
	Mean (SD)	0.8 (0.1)	0.7 (0.1)	0.7 (0.1)	0.8 (0.1)	
<b>Predicted peak flow</b>	n (% non-missing)	193 (55.6)	33 (70.2)	79 (49.1)	40 (72.7)	0.0038
	Mean (SD)	498.0 (73.8)	520.8 (67.3)	533.5 (78.8)	511.6 (70.0)	
<b>Percentage predicted</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0418

<b>peak flow</b>	Mean (SD)	-66.7 (2103.7)	84.5 (17.5)	91.6 (16.0)	86.8 (17.9)	
<b>Rhinitis diagnosis</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0422
	Yes	130 (37.5)	13 (27.7)	74 (46.0)	27 (49.1)	
<b>Acute OCS use (yes/no)</b>	n (% non-missing)	347 (100.0)	47 (100.0)	161 (100.0)	55 (100.0)	0.0486
	Yes	93 (26.8)	12 (25.5)	40 (24.8)	24 (43.6)	

All values in the table are n (%) unless otherwise specified. High FeNO defined as  $\geq 35$  ppb; non-high FeNO  $< 35$  ppb; high blood eosinophil count defined as  $\geq 0.300 \times 10^9$  cells/L; non-high blood eosinophil count  $< 0.300 \times 10^9$  cells/L.

BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV, forced expiratory volume; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; IHD, ischaemic heart disease; IQR, interquartile range; LABA, long-acting  $\beta_2$ -agonist; OCS, oral corticosteroids; ppb, parts per billion; SABA, short-acting  $\beta_2$ -agonist; SD, standard deviation.

Additional file S1: Table 3. Frequency of exacerbations between matched biomarker groups

<b>Categorisation 1</b>
-------------------------

<b>Asthma exacerbations</b>	<b>Non-high FeNO and non-high blood eosinophils (n=27)</b>	<b>High FeNO and high blood eosinophils (n=27)</b>	<b>p-value</b>
n (% non-missing)	27 (100.0)	27 (100.0)	0.0427
0, n (%)	21 (77.8)	13 (48.1)	
1, n (%)	6 (22.2)	8 (29.6)	
2, n (%)	0 (0.0)	4 (14.8)	
3, n (%)	0 (0.0)	2 (7.4)	
Mean # exacerbations (SD)	0.2 (0.4)	0.8 (1.0)	0.0109
	<b>Non-high FeNO and non-high blood eosinophils (n=200)</b>	<b>High FeNO OR high blood eosinophils (n=200)</b>	
n (% non-missing)	173 (100.0)	173 (100.0)	0.0481
0, n (%)	120 (69.4)	120 (69.4)	
1, n (%)	41 (23.7)	28 (16.2)	
2, n (%)	11 (6.4)	19 (11.0)	
3, n (%)	0 (0.0)	5 (2.9)	
4+, n (%)	1 (0.6)	1 (0.6)	
Mean # exacerbations (SD)	0.4 (0.6)	0.5 (0.8)	0.3423
<b>Categorisation 2</b>			
	<b>Non-high FeNO and non-high blood eosinophils (n=186)</b>	<b>Non-high FeNO and high blood eosinophil (n=186)</b>	

n (% non-missing)	186 (100.0)	186 (100.0)	0.2149
0, n (%)	134 (72.0)	128 (68.8)	
1, n (%)	36 (19.4)	31 (16.7)	
2, n (%)	15 (8.1)	20 (10.8)	
3, n (%)	1 (0.5)	6 (3.2)	
Mean # exacerbations (SD)	0.4 (0.7)	0.5 (0.9)	0.3134
	<b>Non-high FeNO and non-high blood eosinophils (n=98)</b>	<b>High FeNO and non-high blood eosinophils (n=98)</b>	
n (% non-missing)	98 (100.0)	98 (100.0)	0.3126
0, n (%)	72 (73.5)	63 (64.3)	
1, n (%)	20 (20.4)	24 (24.5)	
2, n (%)	6 (6.1)	9 (9.2)	
3, n (%)	0 (0.0)	2 (2.0)	
4, n (%)	0 (0.0)	0 (0.0)	
Mean # exacerbations (SD)	0.3 (0.6)	0.5 (0.7)	0.1332
	<b>Non-high FeNO and non-high blood eosinophils (n=53)</b>	<b>High FeNO and high blood eosinophils (n=53)</b>	
n (% non-missing)	53 (100.0)	53 (100.0)	0.3080
0, n (%)	36 (67.9)	29 (54.7)	
1, n (%)	12 (22.6)	14 (26.4)	
2, n (%)	5 (9.4)	8 (15.1)	
3, n (%)	0 (0.0)	2 (3.8)	
Mean # exacerbations	0.4 (0.7)	0.7 (0.9)	0.1166

(SD)			
------	--	--	--

FeNO, fractional exhaled nitric oxide; SD, standard deviation.